Article
Author(s):
Tampere, Finland-Both the M2 Single Use microkeratome and the M2 microkeratome with the new 90-?m head (Moria, Antony, France) have been performing well in clinical trials.
Myopia onset predicted by accelerated eye changes a year in advance
California dreaming: 2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco
Economic burden of late-stage age-related macular degeneration
Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025
Prevent Blindness declares April as Women’s Eye Health and Safety Month
OKYO Pharma releases positive long-term stability data for urcosimod in neuropathic corneal pain